GOOD DIVIDEND
DPHARMA 7148 Share Price
RM1.21
klse: Duopharma Biotech Berhad
Stock Information
Board : Main
Shariah : Shariah Compliant
Sector : Pharmaceuticals
Address: Suite 18.06, Level 18, CIMB HUB No.26, Jalan Sultan Ismail, 50250 Kuala Lumpur
Contact: +603-21620218
Website: https://www.duopharmabiotech.com/
Stock Background
Duopharma Biotech Berhad is engages in the manufacturing and distribution of pharmaceutical products. The company offers consumer healthcare, classic pharmaceutical, and specialty pharmaceutical products. In addition, it offers property management and services; and distributes, imports, and exports chemical products.
Profit Analysis: DPHARMA 7148
|
Result
Quarter Report History
| Date | Revenue,k | PBT,k | Net Profit,k |
|---|---|---|---|
| 14/05/26 | 247,880 | 40,407 | 30,713 |
| 26/02/26 | 224,686 | 24,906 | 19,048 |
| 13/11/25 | 222,486 | 29,682 | 22,571 |
| 21/08/25 | 221,782 | 26,584 | 20,204 |
| 15/05/25 | 262,738 | 33,737 | 25,640 |
| 19/02/25 | 193,671 | 17,443 | 15,083 |
| 08/11/24 | 208,732 | 20,520 | 15,595 |
| 15/08/24 | 218,324 | 21,960 | 16,689 |
| 23/05/24 | 192,968 | 20,101 | 15,277 |
| 22/02/24 | 167,501 | 7,034 | 8,502 |
| 08/11/23 | 169,235 | 11,427 | 8,970 |
| 24/08/23 | 167,516 | 16,515 | 12,541 |
Fundamental
Fundamental Analysis
| Last 4 Quarter Revenue (RM’000) | 917 |
|---|---|
| Last 4 Quarter Net Profit (RM’000) | 92,536 |
| Last 4 Quarter EPS (sen) | 9.62 |
| Last 4 Quarter PER | 12.58 |
| Last 4 Quarter Dividend (sen) | 455.00 |
| Last 4 Quarter Dividend Yield (%) | 3.76 |
| Net Tangible Assets (RM) | 0.79 |
| Goodwill (RM) | 35,870 |
| Cash (RM’000) | 290,870 |
| Debt (RM’000) | 495,360 |
| Total Debt (RM’000) | 713,850 |
| Net Assets (RM’000) | 757,620 |
| Current Ratio | 2.60 |
| Quick Ratio | 1.67 |
| Cash Ratio | 0.92 |
Technical
Technical Analysis
| MACD (26 vs 12) | -1.063 |
|---|---|
| Exponential Moving Average 5 | 1.226 |
| Exponential Moving Average 20 | 1.218 |
| Exponential Moving Average 90 | 1.255 |
| Relative Strength Index 14 | 0.50 |
| Stochastic %D 3 | 0.19 |
| Stochastic %K 14 | 0.29 |
22 reviews for DPHARMA 7148
Show all Most Helpful Highest Rating Lowest Rating
Only logged in customers who have purchased this product may leave a review.
Stock Profit Analysis
-
BNASTRA 7195 ★★★★★RM2.14 - PETRONM 3042 ★★★★★RM3.44
- CMSB 2852 ★★★★★RM1.00
- SUNREIT 5176 ★★★★★RM2.23
Salary Proof
BURSA MALAYSIA –
The group’s PBT increased only marginally from RM83.0 million to RM84.9 million, while our net profit grew by 6.7% from RM65.7 million to RM70.1 million. This was due to the one-off full impairment made for our unsold Sinopharm vaccine stock. Going Forward, The group continue to build their portfolio of products in ways that make a meaningful difference to healthier lives. They have a strong pipeline of drugs that are undergoing the necessary approvals before they can be launched. At the same time, The group are developing their preventive medicine and early detection solutions for the best health outcomes.
BURSA MALAYSIA –
The Group has recorded a revenue of RM151.96 million for current quarter ended 31 December 2022 which is lower as compared to RM177.07 million in the preceding quarter mainly due to lower demand from private ethical sector and public health sector as sales gradually tapered off in the final quarter of the calendar year. Lower sales during the current quarter has resulted in lower Group’s PBT as compared to the preceding quarter
BURSA MALAYSIA –
The Group has recorded a revenue of RM177.07 million for current quarter ended 30 September 2022 which is marginally lower as compared to RM181.74 million in the preceding quarter mainly due to a lower sales to ethical specialty and consumer healthcare market. The Group’s PBT has decreased slightly by 0.41% primarily due to lower sales during the current quarter than preceding quarter.
BURSA MALAYSIA –
The Group has recorded a revenue of RM181.74 million for current quarter ended 30 June 2022 which is marginally lower as compared to RM185.94 million in the preceding quarter mainly due to a lower demand from public health sector and consumer healthcare business. The Group’s PBT has decreased mainly due to lower sales and increase in cost of sales primarily driven by higher impairment of inventories and also higher research and development expenditure were incurred during the current quarter than preceding quarter.
BURSA MALAYSIA –
The Group has recorded a higher revenue and PBT of RM185.94 million and RM26.65 million for the current period ended 31 March 2022 as compared to RM145.44 million and RM17.13 million respectively for the preceding financial quarter. Increase in Group’s revenue was mainly due to higher demand from consumer healthcare, private ethical and public health sector. Higher revenue throughout the current quarter led to higher PBT as compared to preceding financial quarter.
BURSA MALAYSIA –
The Group’s revenue declined to RM145.44 million for current quarter ended 31 December 2021 as compared to RM171.84 million in the preceding quarter mainly due to lower demand from private ethical sector and public health sector as sales gradually tapered off in the final quarter of the calendar year. The Group’s PBT decreased by 23.82% to RM17.13 million in the current quarter as compared to RM22.48 million in the preceding financial quarter, mainly due to lower sales and higher expenditures in the current quarter.
BURSA MALAYSIA –
The revenue increased from Q2,2021 to Q3,2021 is mainly attributable to the sale of antigen kits ventured into by G3 Group in the month of September 2021. However, the increased losses in Q3,2021 from Q2,2021 are mainly attributable to the impairment of debt amounting to RM2.5m in relation to outstanding balance yet to be received from the acquirer of apparel business.
BURSA MALAYSIA –
The Group’s revenue decreased to RM155.4 million for current quarter ended 30 June 2021 as compared to RM166.5 million in the preceding quarter mainly due to a lower demand from public health sector and ethical specialty business. Decrease in sales has led to lower PBT which decreased from RM23.2 million in preceding quarter to RM20.2 million in current quarter ended 30 June 2021.